Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

Phosphate binders work by forming an insoluble phosphate ... hyperparathyroidism in CKD stages 3 and 4 CKD = chronic kidney disease. Cinacalcet is a calcimimetic indicated to treat secondary ...

Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherenceLOS ALTOS, ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate binders is a significant challenge contributing to ...

By 1970 the administration of aluminium hydroxide and/or calcium carbonate as phosphate binders in dialysis patients was virtually universal practice. In 1972, Alfrey was one of the first to ...

The review draws attention to the high non-adherence rates to phosphate binders, which are crucial in managing hyperphosphatemia in dialysis patients. Non-adherence rates range from 22% to 74% ...